Thermodynamic Allosteric Stabilization and Oral Bio-Encapsulation for 1q21 GBA1 Gaucher Disease: Overcoming the ΔΔ Gfold Unfolding Barrier, Eliminating the Lyso-GL1 Myeloma Clonal Hazard, and Hardware-Gating Statutory Subsidy Continuity via PHOENIX_ROUTER

Standard-of-care intravenous Enzyme Replacement Therapy (ERT; imiglucerase, velaglucerase alfa) for Gaucher disease (chromosome 1q21 GBA1 deficiency; OMIM 230800, 230900, 231000) imposes an unsustainable macroeconomic and household burden—exceeding JPY 160,000 per month in out-of-pocket patient co-payments upon loss of pediatric coverage and JPY 25,000,000–45,000,000 annually in gross national health expenditure per patient. This cost structure stems from three fundamental bottlenecks: (1) mammalian Chinese Hamster Ovary (CHO) bioreactor cultivation coupled with multi-step exoglycosidase glycan remodeling to expose terminal alpha-D-mannose residues; (2) severe thermodynamic destabilization (ΔΔ Gfold = +4.8 ± 0.4 kcal/mol) in East Asian prevalent neuropathic/visceral alleles such as p.Leu483Pro (L444P) and RecNciI, which drives premature endoplasmic reticulum-associated degradation (ERAD) and rapid plasma inactivation; and (3) catastrophic splenic and bone-marrow accumulation of deacylated glucosylsphingosine (Lyso-GL1) via acid ceramidase (ASAH1) whenever treatment access uₜₓ(a) is interrupted at the age-18/20 statutory pediatric-to-adult transition cliff, exponentially accelerating CD1d-mediated Type II NKT cell stimulation, monoclonal gammopathy of undetermined significance (MGUS), and multiple myeloma (MM) somatic clonal evolution hₛₒₘ(a). Building directly upon the thermodynamic foundations of Treatise V, this monograph establishes Treatise VI: a rigorous mathematical, pharmacokinetic/pharmacodynamic (PK/PD), and hardware-enforced roadmap to compress Gaucher disease therapeutic unit costs by over two orders of magnitude (>= 100x, to JPY 100–1,000 per daily oral dose) while guaranteeing uninterrupted splenic/marrow substrate clearance ("flushing the macrophage lysosomal backlog"). We formalize three synergistic therapeutic architectures: (i) AI-designed non-competitive allosteric pharmacological chaperones targeting the Domain III hydrophobic core of L444P acid beta-glucocerebrosidase (GCase) with binding free energy Δ Gbind <= -4.5 kcal/mol and an acidic lysosomal dissociation switch (pK_a ~ 5.2); (ii) glyco-engineered methylotrophic yeast (Komagataella phaffii) and plant-seed (Oryza sativa) oral micro-encapsulated GCase leveraging M-cell Peyer's patch lymphatic translocation; and (iii) hyper-stabilized de novo engineered Super-GCase (ΔΔ Gfoldᵉⁿᵍ <= -3.2 kcal/mol) encapsulated in phosphatidylserine/mannose-targeted liposomes. Finally, we integrate this ultra-low-cost therapeutic pipeline with the PHOENIX_ROUTER zero-knowledge hardware interlock over the 64-bit Goldilocks prime field F_p (p = 2^64 - 2^32 + 1) and the NLL-v1.0-2026 / RTO P2.0 optical data diode, physically clamping administrative subsidy-termination write-enable lines (WE_STATE_ROOT = 0V in < 3.2 ns) and preventing unauthorized external AI scraping of Japanese patient haplotype tensors.